Evidence map›Paper›PMID 29402706›Full record

ArticleClinical genitourinary cancer2018

Association Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Outcome of Patients With Metastatic Renal-Cell Carcinoma Treated With Nivolumab.

Mehmet Asim Bilen, Giselle Marie Almeida Dutcher, Yuan Liu, Deepak Ravindranathan, Haydn T Kissick, Bradley C Carthon, Omer Kucuk, Wayne B Harris, Viraj A Master

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical genitourinary cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 6 pooled it
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 6 syntheses or guidelines pooled it, 106 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Article
  9. Tumor-educated cells in tumor microenvironment: Key drivers of immunotherapy resistance.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025
    Article
  10. Article
  11. Review
  12. Article
  13. Observational
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Mehmet Asim BilenDepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA. Electronic address: mbilen@emory.edu.
Giselle Marie Almeida DutcherDepartment of Medicine, Internal Medicine Residency Program, Emory University, Atlanta, GA.
Yuan LiuDepartment of Biostatistics and Bioinformatics, Emory University, Atlanta, GA.
Deepak RavindranathanDepartment of Medicine, Internal Medicine Residency Program, Emory University, Atlanta, GA.
Haydn T KissickDepartment of Urology, Emory University, Atlanta, GA.
Bradley C CarthonDepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA.
Omer KucukDepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA.
Wayne B HarrisDepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA.
Viraj A MasterDepartment of Urology, Emory University, Atlanta, GA.
Emory University · US

Funding

Winship Cancer Institute Cancer Center Support GrantP30CA138292 · NCI · EMORY UNIVERSITY · PI Suresh S Ramalingam · 2009 to 2026
$47.5M
NCI NIH HHS P30 CA138292
6 · The paper itself

Abstract

backgroundBiomarkers to guide treatment in metastatic renal-cell carcinoma (mRCC) are lacking. We aimed to investigate the association between pretreatment neutrophil-to-lymphocyte ratio (NLR) and outcome of patients with mRCC receiving nivolumab. PATIENTS AND

methodsThrough retrospective chart review, we identified 38 patients with mRCC treated with standard-of-care nivolumab between 2015 and 2016 at Winship Cancer Institute of Emory University. NLR was determined from complete blood count collected before starting treatment, and imaging was performed to assess progression. The NLR cutoff value of 5.5 was determined by log-rank test, and the univariate association with overall survival (OS) or progression-free survival (PFS) was assessed by the Cox proportional hazard model and Kaplan-Meier method.

resultsThe 38 patients had a median age of 69 years. The PFS and OS for all patients at 12 months was 54% and 69%, respectively. The median PFS was 2.6 months in the high NLR group but not reached in the low NLR group. Low NLR was strongly associated with increased PFS with hazard ratio of 0.20 (95% confidence interval, 0.07-0.64; P = .006). The median OS was 2.7 months in the high NLR group but not reached in the low NLR group. Low NLR was significantly associated with a prolonged OS with hazard ratio of 0.06 (95% confidence interval, 0.01-0.55; P = .012).

conclusionPretreatment NLR < 5.5 is associated with superior PFS and OS. NLR is a biomarker that can inform prognosis for patients with mRCC and should be further validated in larger cohorts and in prospective studies.

Indexed as

AdultAgedAged, 80 and overAntineoplastic Agents, ImmunologicalCarcinoma, Renal CellFemaleHumansKidney NeoplasmsLymphocyte CountMaleMiddle AgedNeutrophilsNivolumabPrognosisProgression-Free SurvivalProspective StudiesAntineoplastic Agents, ImmunologicalNivolumabAnti-PD-1 antibodyBiomarkerImmune checkpoint inhibitorImmunotherapyKidney cancer

Identifiers

PMID29402706
PMCPMC5970007
OpenAlexW2782319564

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.